鉴于相关制度修订及换届工作尚在筹备中，为保证公司董事会、监事会相关 工作的连续性和稳定性，公司董事会、监事会的换届选举工作将适当延期，董事 会各专门委员会、高级管理人员的任期亦相应顺延。在董事会、监事会换届选举 工作完成前，公司第六届董事会、监事会全体成员、董事会各专门委员会成员及 高级管理人员将依照相关法律法规和《公司章程》等的规定，继续履行董事、监 事及高级管理人员的职责和义务。 公司董事会、监事会延期换届不会影响公司的正常运营。公司将积极推进相 关工作，尽快完成董事会与监事会的换届选举工作并及时履行信息披露义务。 证券代码：688319 证券简称：欧林生物 公告编号：2025-017 成都欧林生物科技股份有限公司关于董事会、监事会 延期换届及独立董事任期届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会、监事会延期换届 成都欧林生物科技股份有限公司(以下简称"公司")第六届董事会、监事会 任期将于 2025 年 5 月 18 日届满。公司拟根据中国证券监督管理委员会最新修订 的《上市公司章程 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-017 二、独立董事任期届满 根据《上市公司独立董事管理办法》等相关规定，上市公司独立董事占董事 会成员的比例不得低于三分之一，且独立董事在上市公司连续任职时间不得超过 六年。公司现任独立董事何少平先生、李先纯先生及王乔先生的任期于 2025 年 5 月届满且连任时间满 6 年，即将任期届满离任。鉴于各位独立董事任期届满离任 将导致公司独立董事人数少于董事会成员的三分之一，根据《上市公司独立董事 管理办法》等相关规定，在董事会换届工作完成以前，何少平先生、李先纯先生 及王乔先生将继续履行其独立董事及相关董事会专门委员会委员职责，直至公司 股东大会选举产生新的独立董事。 一、董事会、监事会延期换届 成都欧林生物科技股份有限公司(以下简称"公司")第六届董事会、监事会 任期将于 2025 年 5 月 18 日届满。公司拟根据中国证券监督管理委员会最新修订 的《上市公司章程指引》《关于新<公司法>配套制度规则实施相关过渡期安排》 及上海证券交易所发布的配套规则制度等要求修订《成都欧林生物科技股份有限 公司章程》（以下简称"《公司章程》"）及相关内部制度 ...

Investment Rating - The report does not explicitly state an investment rating for the vaccine industry Core Insights - The overall trend in the vaccine industry shows a decline in batch approvals for most vaccine types in Q1 2025, with some exceptions showing recovery or growth in demand [7][29][46] Summary by Category Multi-Component Vaccines - In Q1 2025, multi-component vaccines saw a total of 17 batch approvals, a decrease of 26% compared to the previous year [11][15] - The five-component vaccine maintained its batch approval at 17, while the four-component vaccine had no approvals [15][12] Pneumonia Vaccines - Total batch approvals for pneumonia vaccines in Q1 2025 were 23, down 30% year-on-year [19][21] - The 13-valent pneumonia vaccine had 19 approvals, remaining stable, while the 23-valent vaccine saw a significant drop to 4 approvals, down 71% [24][19] HPV Vaccines - HPV vaccine approvals increased to 57 batches in Q1 2025, a growth of 63% [29][27] - The two-valent HPV vaccine saw a remarkable increase of 367%, with all approvals coming from Wantai Biological Pharmacy [29][32] Influenza Vaccines - Influenza vaccine approvals totaled 29 batches, a significant increase of 263% year-on-year [34][38] - The three-valent influenza vaccine had 28 approvals, while the four-valent vaccine had only 1 approval, down 67% [38][41] Rabies Vaccines - Batch approvals for rabies vaccines increased to 223 in Q1 2025, a growth of 37% [46][48] - The freeze-dried rabies vaccine accounted for the majority of approvals, with Chengda Biological achieving 105 approvals, a 110% increase [48][46] Varicella Vaccines - Varicella vaccine approvals slightly decreased to 83 batches, down 2% [53][54] - The largest contributor was Baike Biological, with 33 approvals, marking a 38% increase [54][53] Hib Vaccines - Hib vaccine approvals fell to 7 batches, a decrease of 50% [59][58] EV71 Vaccines - EV71 vaccine approvals continued to decline, with only 4 batches approved, down 69% [64][63] Rotavirus Vaccines - Rotavirus vaccine approvals totaled 21 batches, a decrease of 46% [68][67] DTP Vaccines - DTP vaccine approvals increased to 18 batches, a growth of 167% [72][73] Meningitis Vaccines - Meningitis vaccine approvals totaled 85 batches, down 34% [78][79] - The AC polysaccharide vaccine accounted for 55 approvals, a decrease of 47% [84][79] Hepatitis B Vaccines - Hepatitis B vaccine approvals increased to 87 batches, a growth of 28% [91][90] IPV Vaccines - IPV vaccine approvals totaled 22 batches, a decrease of 33% [93][92]

经济观察网讯 5月6日重点关注的财经要闻与资本市场大事： （原标题：今日看点｜北交所为试点股票启用新证券代码） 5月6日，21家公司共发布21个股票回购相关进展。其中，2家公司首次披露股票回购预案，14家公司披 露股票回购实施进展，5家公司回购方案已实施完毕。 从首次披露回购预案来看，当日共1家公司股票回购预案金额超千万。科思科技、毅昌科技回购预案金 额最高，分别拟回购不超5000.0万元、66.36万元。从回购实施进展来看，美的集团、长春高新、九安医 疗回购金额最高，分别回购5.54亿元、4.0亿元、3.7亿元。从已完成回购来看，当日共4家公司回购金额 超千万。华工科技、天茂集团、万邦德已完成回购金额最高，分别回购3.95亿元、9998.26万元、 5998.85万元。 4、美国3月贸易帐、欧元区3月PPI月率等数据将公布。 （数据来源Wind，内容不构成任何投资建议） 1、北交所为试点股票启用新证券代码 近日，北交所发布通知，北交所存量上市公司代码切换试点工作总体准备就绪，拟于2025年5月6日正式 上线。根据通知，2025年5月1日至2025年5月5日期间，北交所组织开展代码切换与通关测试，自2025年 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and clinical trial progress [1][2]. Core Insights - The company reported a revenue of 589 million yuan in 2024, representing a year-on-year increase of 18.69%, and a net profit of 21 million yuan, also up by 18.24% [1][2]. - The first quarter of 2025 saw a revenue of 87 million yuan, a 23.58% increase year-on-year, although it reported a net loss of 7 million yuan, which is a 72.79% improvement compared to the previous year [1][2]. - The company is actively advancing its clinical trials for the recombinant pneumococcal vaccine, with over 5,600 participants enrolled as of March 2025, and expects to complete enrollment in the first half of 2025 [2]. Financial Performance Summary - In 2024, the company achieved total revenue of 589 million yuan, with a breakdown showing the tetanus vaccine revenue at 536 million yuan (up 15.73% year-on-year) and the meningococcal vaccine revenue at 26 million yuan (up 580.49% year-on-year) [2]. - The gross margin for the first quarter of 2025 improved by 1 percentage point to 93.43%, while management and R&D expense ratios decreased significantly [2]. - Revenue projections for 2025 to 2027 are estimated at 677 million yuan, 773 million yuan, and 869 million yuan, with corresponding net profits of 23 million yuan, 43 million yuan, and 60 million yuan [2][4]. Clinical Development Pipeline - The company is progressing with its pipeline of vaccines targeting superbugs, including the Helicobacter pylori vaccine, Pseudomonas aeruginosa vaccine, and Acinetobacter baumannii vaccine [2]. - The Helicobacter pylori vaccine has received Phase I clinical trial approval in Australia, and the company is optimizing the oral formulation for future domestic clinical trial applications [2]. Valuation Metrics - The projected P/E ratios for 2025, 2026, and 2027 are approximately 276, 148, and 105, respectively, indicating a high valuation relative to earnings [3][4].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and clinical trial progress [1][2]. Core Insights - The company reported a revenue of 589 million yuan in 2024, representing a year-on-year increase of 18.69%, and a net profit of 21 million yuan, also up by 18.24% [1][2]. - The company is experiencing strong growth in its Tetanus vaccine segment, with a revenue of 536 million yuan in 2024, an increase of 15.73% year-on-year [2]. - The company is actively advancing its clinical trials for the recombinant Staphylococcus aureus vaccine, with over 5,600 participants enrolled as of March 2025, and expects to complete enrollment in the first half of 2025 [2]. Financial Performance Summary - In 2024, the company achieved total revenue of 589 million yuan, with a year-on-year growth rate of 18.69% [4]. - The net profit attributable to the parent company for 2024 was 21 million yuan, reflecting an 18.24% increase year-on-year [4]. - The gross profit margin for 2024 was reported at 94.4%, indicating strong profitability [4]. - The company forecasts revenues of 677 million yuan, 773 million yuan, and 869 million yuan for 2025, 2026, and 2027 respectively, with corresponding year-on-year growth rates of approximately 15%, 14%, and 13% [2][4]. Product and Market Analysis - The company’s product portfolio includes the Tetanus vaccine, which has shown consistent growth, and the newly developed Staphylococcus aureus vaccine, which is in advanced clinical trials [2]. - The company also has a pipeline of vaccines targeting superbugs, including Helicobacter pylori, Pseudomonas aeruginosa, and Acinetobacter baumannii, indicating a robust research and development strategy [2]. Earnings Forecast - The projected net profits for 2025, 2026, and 2027 are 23 million yuan, 43 million yuan, and 60 million yuan respectively, with growth rates of approximately 10%, 86%, and 40.8% [2][4]. - The earnings per share (EPS) are expected to increase from 0.06 yuan in 2025 to 0.15 yuan in 2027 [4][6]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 276.02 in 2025 to 105.30 in 2027, indicating improving valuation as earnings grow [4][6]. - The price-to-book (P/B) ratio is expected to decline from 75.93 in 2025 to 47.77 in 2027, reflecting a strengthening financial position [6].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人樊绍文、主管会计工作负责人谭勇及会计机构负责人（会计主管人员）秦星瑶保证季度报告 中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688319 证券简称：欧林生物 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-016 成都欧林生物科技股份有限公司关于参加 2024 年度科创板创新药行业集体业绩说明会 暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 04 月 28 日(星期一)至 05 月 07 日(星期三)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@olymvax.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 成都欧林生物科技股份有限公司（以下简称"公司"）已于 2025 年 3 月 29 日发布公司 2024 年年度报告并于 2025 年 4 月 26 日发布公司 2025 年第一季度报 告，为便于广大投资者更全面深入地了解公司 2024 年及 2025 年第一季度的经营 成果、财务状况，公司计划于 2025 年 05 月 08 日(星期四)下午 15:00-17:00 参 加2024年度科创板创新药行业集体业绩说明会并同时 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0174 | -0.0641 | 72.85 | 0.0095 | | 每股净资产（元） | 2.27 | 2.2 | 3.18 | 2.18 | | 每股公积金(元) | 1.5 | 1.5 | 0 | 1.43 | | 每股未分配利润(元) | -0.25 | -0.30 | 16.67 | -0.26 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.87 | 0.71 | 22.54 | 0.67 | | 净利润(亿元) | -0.07 | -0.26 | 73.08 | 0.04 | | 净资产收益率(%) | -0.77 | -2.87 | 73.17 | 0.44 | | 持有数量(万股) 名称 | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股 ...